分泌抗CD33/抗CD3双靶向抗体的CD70 CAR T细胞克服急性髓系白血病抗原异质性
研究针对CD70单抗原靶向在体内出现抗原逃逸的局限,将优化CD70 CAR改造为分泌靶向CD33的双特异性T细胞衔接抗体分子(TEAM,7033)。7033 CAR T细胞在体外对CD33或CD70单抗原敲除肿瘤介导特异性细胞毒作用,在体内混合肿瘤模型和患者来源异种移植中清除肿瘤并优于既往优化CD70 CAR;CD33 TEAM可重定向既往接受大量细胞毒治疗的患者T细胞活化、分泌细胞因子并杀伤肿瘤。作者认为该7033 CAR克服AML异质性具可行性,值得进一步研究。
要点
- CD70单抗原靶向在体内可出现CD70抗原逃逸,为单抗原靶向的局限。
- 7033 CAR T细胞在CD70抗原逃逸混合肿瘤模型中清除肿瘤,并优于既往优化CD70 CAR。
- CD33 TEAM可重定向既往接受大量细胞毒治疗的患者T细胞活化、分泌细胞因子并杀伤肿瘤。
核心结论
- 研究结果证明7033 CAR克服AML异质性并利用患者旁观者T细胞具可行性,该方法值得在此迫切临床需求的患者中进一步研究。
研究设计与样本
- 研究将优化CD70靶向配体基CAR平台改造为分泌靶向CD33的双特异性T细胞衔接抗体分子(TEAM,7033),并在AML细胞系、CD33或CD70单抗原敲除肿瘤、体内混合肿瘤模型和患者来源异种移植中评价。
主要发现
- CD33 TEAMs在AML细胞系中介导特异性细胞毒作用,包括CD33或CD70单抗原敲除肿瘤。
- 7033 CAR T细胞在CD70抗原逃逸的体内混合肿瘤模型中清除肿瘤,并在患者来源异种移植中优于既往优化CD70 CAR。
- CAR T细胞体内基因表达谱显示7033 CAR T细胞在持久性、活化和T细胞受体信号通路评分增强。
- CD33 TEAMs成功重定向从AML患者分离的T细胞活化、分泌细胞因子并杀伤肿瘤靶标,尽管这些患者既往接受大量细胞毒治疗。
临床怎么用
- 作者认为7033 CAR克服AML异质性并利用患者旁观者T细胞具可行性,该方法值得在此迫切临床需求的患者中进一步研究。
局限性
- 原文指出单抗原靶向的局限为体内出现CD70抗原逃逸。
- 原文结论提出该方法值得在此迫切临床需求的患者中进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD70 has emerged as a promising target in acute myeloid leukemia (AML), and we have previously demonstrated the potency of an optimized CD70-targeted ligand-based chimeric antigen receptor (CAR). However, here, we identify in vivo CD70 antigen escape as a limitation of single-antigen targeting. Combination targeting of CD70 and CD33 may overcome AML antigen heterogeneity. We hypothesized that modifying our CD70 CAR platform to secrete a bispecific T-cell engaging antibody molecule (TEAM) targeting CD33 (7033) would create a therapeutic window whereby AML heterogeneity could be addressed without increasing tissue toxicity. We found that CD33 TEAMs mediated specific cytotoxicity across AML cell lines, including CD33 or CD70 single-antigen knockout tumors. 7033 CAR T cells eradicated tumor in an in vivo mixed tumor model of CD70 antigen escape and outperformed the previously optimized CD70 CAR in a patient-derived xenograft. In vivo gene expression profiling of CAR T cells revealed enhanced 7033 CAR T-cell pathway scoring for persistence, activation, and T-cell receptor signaling. Additionally, CD33 TEAMs successfully redirected T cells isolated from patients with AML to activate, secrete cytokines, and kill tumor targets despite exposure to substantial prior cytotoxic therapies. In summary, our findings demonstrate the feasibility of our 7033 CAR to overcome AML heterogeneity and leverage the bystander T cells of patients; this approach warrants further study in patients with this dire clinical need.
引用
- Silva HJ, Martin G, Birocchi F, et al. CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML. Blood. 2025. PMID: 39571145. doi:10.1182/blood.2023023210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。